| Project/Area Number |
24701033
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Clinical oncology
|
|---|
| Research Institution | Kagoshima University |
|---|
Principal Investigator |
IJICHI Nobuhiro 鹿児島大学, 大学院・医歯学総合研究科, 助教 (80380624)
|
|---|
| Project Period (FY) |
2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 内分泌療法 / 乳がん / エストロゲン / FOXP1 / 次世代シーケンサー / FOXA1 / Erα / タモキシフェン耐性 |
|---|
| Research Abstract |
To identify the novel diagnostic and therapeutic factors for endocrine therapy-resistant breast cancer, we focused on FOXP1, one of a forkhead transcription factor family, as a candidate, and its genome-wide distributionin ERα-positive breast cancer MCF-7 cells was examined by next-generation sequencing strategy. We demonstrated that majority of binding regions of FOXP1 in MCF-7 cells stimulated with estrogen were overlapped with those of both Erαand FOXA1. We also demonstrated that the double-positive immunoreactivities of FOXP1 and FOXA1 are significantly associated with a favorable prognosis for survival of breast cancer patients receiving adjuvant tamoxifen therapy. In this study, we revealed that, similar to FOXA1, FOXP1 is assumed to be a critical transcription factor for Erαsignaling, and both forkhead transcription factors can serve as predictive factors for acquired endocrine resistance in breast cancer.
|
